ValiRx (LON:VAL) Trading Down 50% – Should You Sell?

ValiRx plc (LON:VAL) traded down 50% during trading on Monday . The company traded as low as GBX 0.72 ($0.01) and last traded at GBX 0.80 ($0.01). 810,556 shares were traded during mid-day trading, a decline of 18% from the average session volume of 982,826 shares. The stock had previously closed at GBX 1.60 ($0.02).

ValiRx Stock Up 3.2 %

The company has a quick ratio of 1.27, a current ratio of 6.65 and a debt-to-equity ratio of 0.49. The firm has a market cap of £1.06 million, a P/E ratio of -38.75 and a beta of 0.59. The business has a fifty day moving average of GBX 1.52 and a 200 day moving average of GBX 2.13.

ValiRx Company Profile

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer.